Wiener klinische Wochenschrift

, Volume 120, Issue 19–20, pp 631–641

Anale HPV-Infektionen

  • Felix Aigner
  • Friedrich Conrad
  • Andreas Widschwendter
  • Robert Zangerle
  • Bettina Zelger
  • Alfred Haidenberger
  • Sebastian Roka
  • Kurt Heim
  • Reinhard Höpfl
  • Martin Klimpfinger
  • Yves Marcus Rigler
  • Hugo Bonatti
  • Johann Pfeifer
  • Andrea Maier
  • Reinhard Kirnbauer
  • Andreas Salat


HPV Anogenital infection HIV MSM Vaccination 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bosch FX, de Sanjose S (2003) Chapter 1: Human papillomavirus and cervical cancer – burden and assessment of causality. J Natl Cancer Inst Monogr 31: 3–13PubMedCrossRefGoogle Scholar
  2. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al (2000) Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 87 (2): 221–227PubMedCrossRefGoogle Scholar
  3. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, et al (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12 (6): 485–490PubMedGoogle Scholar
  4. Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, et al (2004) Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. JID 190: 2070–2076PubMedCrossRefGoogle Scholar
  5. Manning SE, Thorpe LE, Ramaswamy C, Hajat A, Marx MA, Karpati AM, et al (2007) Estimation of HIV prevalence, risk factors, and testing frequency among sexually active men who have sex with men, aged 18–64 years – New York City, 2002. J Urban Health 84 (2): 212–225PubMedPubMedCentralCrossRefGoogle Scholar
  6. Salat A, Handisurya A, Trost A, Roka J, Roka F, Schalk H, et al (2006) 23rd International Papillomavirus Conference, PragGoogle Scholar
  7. Van der Snoek EM, Niesters H, Mulder P, van Doornum G, Osterhaus A, van der Meijden W (2003) Human papillomavirus infection in men who have sex with men participating in a Dutch Gay-Cohort Study. STD 30: 639–644CrossRefGoogle Scholar
  8. Chin-Hong P, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, et al (2005) Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst 97: 896–905PubMedCrossRefGoogle Scholar
  9. Critchlow CW, Surawicz CM, Holmes KK, Kuypers J, Daling JR, Hawes SE, et al (1995) Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS 9 (11): 1255–1262PubMedCrossRefGoogle Scholar
  10. Hoepfl R, Petter A, Thaler P, Sarcletti M, Widschwendter A, Zangerle R (2003) High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study. BMC Infect Dis 30: 3–6Google Scholar
  11. Melbye M, Palefsky J, Gonzales J, Ryder LP, Nielsen H, Bergmann O, et al (1990) Immune status as a determinant of human papillomavirus detection and its association with anal epithelial abnormalities. Int J Cancer 46 (2): 203–206PubMedCrossRefGoogle Scholar
  12. Palefsky JM, Shiboski S, Moss A (1994) Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr 7 (6): 599–606PubMedGoogle Scholar
  13. Martin F, Bower M (2001) Anal intraepithelial neoplasia in HIV positive people. Sex Transm Infect 77 (5): 327–331PubMedPubMedCentralCrossRefGoogle Scholar
  14. Bjorge T, Engeland A, Luostarinen T, Mork J, Gislefoss RE, Jellum E, et al (2002) Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer 87 (1): 61–64PubMedPubMedCentralCrossRefGoogle Scholar
  15. Critchlow CW, Hawes SE, Kuypers JM, Goldbaum GM, Holmes KK, Surawicz CM, et al (1998) Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS 12 (10): 1177–1184PubMedCrossRefGoogle Scholar
  16. Ogunbiyi OA, Scholefield JH, Raftery AT, Smith JH, Duffy S, Sharp F, et al (1994) Prevalence of anal human papillomavirus infection and intraepithelial neoplasia in renal allograft recipients. Br J Surg 81 (3): 365–367PubMedCrossRefGoogle Scholar
  17. Palefsky JM, Holly EA, Ralston ML, Jay N (1998) Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 177 (2): 361–367PubMedCrossRefGoogle Scholar
  18. Palefsky JM, Holly EA, Ralston ML, Arthur SP, Jay N, Berry JM, et al (1998) Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 17 (4): 320–326PubMedCrossRefGoogle Scholar
  19. Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, et al (1987) Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 317 (16): 973–977PubMedCrossRefGoogle Scholar
  20. Holly EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ, Kristiansen JJ (1989) Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 81 (22): 1726–1731PubMedCrossRefGoogle Scholar
  21. Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al (1998) Spectrum of AIDS-associated malignant disorders. Lancet 351: 1833–1839PubMedCrossRefGoogle Scholar
  22. Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92 (18): 1500–1510PubMedCrossRefGoogle Scholar
  23. Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, et al (2004) HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 37: 1563–1565PubMedCrossRefGoogle Scholar
  24. Palefsky JM, Holly EA, Efirdc JT, Da Costa M, Jay N, Berry JM, et al (2005) Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 19: 1407–1414PubMedCrossRefGoogle Scholar
  25. Fagan SP, Bellows CF, Albo D, Rodriquez-Barradas M, Feanny M, Awad SS, et al (2005) Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma. Am J Surg 190: 732–735PubMedCrossRefGoogle Scholar
  26. Swan MC, Furniss D, Cassell OCS (2004) Surgical management of metastatic inguinal lymphadenopathy. BMJ 329: 1272–1276PubMedPubMedCentralCrossRefGoogle Scholar
  27. Berthier S, Mougin C, Vercherin P, Desmurs H, Gil H, de Wazieres B, et al (1999) Does a particular risk associated with papillomavirus infections exist in women with lupus? Rev Med Interne 20 (2): 128–132PubMedCrossRefGoogle Scholar
  28. Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F, Salat A (2004) Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl Int 17 (7): 366–369PubMedCrossRefGoogle Scholar
  29. Adami J, Gäbel H, Lindelöf B, Ekbom A, Adami HO, Granath F (2003) Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 89: 1221–1227PubMedPubMedCentralCrossRefGoogle Scholar
  30. Frisch M, Melbye M, Moller H (1993) Trends in incidence of anal cancer in Denmark. BMJ 13: 419–422CrossRefGoogle Scholar
  31. Zur Hausen H (1999) Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin Cancer Biol 9 (6): 405–411PubMedCrossRefGoogle Scholar
  32. Daling JR, Sherman KJ, Hislop TG, Maden C, Mandelson MT, Beckmann AM, et al (1992) Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 135 (2): 180–189PubMedGoogle Scholar
  33. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al (2004) Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101 (2): 270–280PubMedCrossRefGoogle Scholar
  34. Durante AJ, Williams AB, Da Costa M, Darragh TM, Khoshnood K, Palefsky JM (2003) Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev 12 (7): 638–642PubMedGoogle Scholar
  35. Einstein MH, Kadish AS (2004) Anogenital neoplasia in AIDS. Curr Opin Oncol 16 (5): 455–462PubMedCrossRefGoogle Scholar
  36. Friedman HB, Saah AJ, Sherman ME, Busseniers AE, Blackwelder WC, Kaslow RA, et al (1998) Human papillomavirus, anal squamous intraepithelial lesions, and human immunodeficiency virus in a cohort of gay men. J Infect Dis 178 (1): 45–52PubMedCrossRefGoogle Scholar
  37. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, et al (1997) Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337 (19): 1350–1358PubMedCrossRefGoogle Scholar
  38. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM (2001) Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 93 (11): 843–849PubMedCrossRefGoogle Scholar
  39. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM (2001) Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 183 (3): 383–391PubMedCrossRefGoogle Scholar
  40. Patel HS, Silver AR, Northover JM (2007) Anal cancer in renal transplant patients. Int J Colorectal Dis 22 (1): 1–5PubMedCrossRefGoogle Scholar
  41. Van der Snoek EM, Niesters HG, van Doornum GJ, Mulder PG, Osterhaus AD, van der Meijden WI (2005) Acquisition and clearance of perianal human papillomavirus infection in relation to HIV-positivity in men who have sex with men in the Netherlands. Acta Derm Venereol 85 (5): 437–443PubMedCrossRefGoogle Scholar
  42. Zbar AP, Fenger C, Efron J, Beer-Gabel M, Wexner SD (2002) The pathology and molecular biology of anal intraepithelial neoplasia: comparisons with cervical and vulvar intraepithelial carcinoma. Int J Colorectal Dis 17 (4): 203–215PubMedCrossRefGoogle Scholar
  43. Caruso ML, Valentini AM (1999) Different human papillomavirus genotypes in ano-genital lesions. Anticancer Res 19 (4B): 3049–3053PubMedGoogle Scholar
  44. Stein E (2003) Humane Papillomaviren. In: Stein E (Hrsg) Proktologie, Lehrbuch und Atlas, 4. Aufl. Springer, Berlin Heidelberg, S 161–178CrossRefGoogle Scholar
  45. Gross G (2006) Condylomata acuminata und andere HPV-assoziierte Krankheitsbilder von Genitale, Anus und Harnröhre. Leitlinien der Deutschen STD-Gesellschaft. Available at: Accessed 11 July
  46. Fleshner PR, Chalasani S, Chang GJ, Levien DH, Hyman NH, Buie WD and The Standards Practice Task Force of The American Society of Colon and Rectal Surgeons (2008) Practice parameters for anal squamous neoplasms. Dis Colon Rectum 51: 2–9PubMedCrossRefGoogle Scholar
  47. Zimmermann F, Adam M, Tympner C, Stollfuß J, Nüssler V (2007) Diagnostik und Therapie des Analkarzinoms. Coloproctology 29 (1): 23–36CrossRefGoogle Scholar
  48. Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM (1997) Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum 40 (8): 919–928PubMedCrossRefGoogle Scholar
  49. Hamilton SR, Aaltonen LA (eds) (2000) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. IARC Press, Lyon, pp 145–155Google Scholar
  50. LeBoit PE, Burg G, Weedon D, Sarasain A (eds) (2006) World Health Organization Classification of Tumours. Pathology and genetics of skin tumours. IARC Press, Lyon, pp 26–29Google Scholar
  51. Wittekind C, Meyer HF, Bootz F (eds) (2003) UICC International Union Against Cancer. TNM Klassifikation maligner Tumoren. 7th edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  52. Tarantino D, Bernstein MA (2002) Endoanal ultrasound in the staging and management of squamous-cell carcinoma of the anal canal. Potential implications of a new ultrasound staging system. Dis Colon Rectum 45: 16–22PubMedCrossRefGoogle Scholar
  53. Sudol-Szopinska I, Szczepkowski M, Jakubowski W (2001) Anal ultrasound in the diagnosis of anal carcinoma. Radiol Oncol 35: 273–276Google Scholar
  54. Centers for Disease Control and Prevention (2006) Sexually transmitted diseases treatment guidelines. MMWR 55 (No. RR-11): 62–67Google Scholar
  55. Lipke MM (2006) An armamentarium of wart treatments. Clin Med Res 4 (4): 273–293PubMedPubMedCentralCrossRefGoogle Scholar
  56. Sterling JC, Handfield-Jones S, Hudson PM; British Association of Dermatologists (2001) Guidelines for the management of cutaneous warts. Br J Dermatol 144: 4–11PubMedCrossRefGoogle Scholar
  57. Arican O, Guneri F, Bilgic K, Karaoglu A (2004) Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol 31 (8): 627–631PubMedCrossRefGoogle Scholar
  58. Moore RA, Edwards JE, Hopwood J, Hicks D (2001) Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 1 (1): 3PubMedPubMedCentralCrossRefGoogle Scholar
  59. Schofer H, Van Ophoven A, Henke U, Lenz T, Eul A (2006) Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol 16 (6): 642–648PubMedGoogle Scholar
  60. Cusini M, Salmaso F, Zerboni R, Carminati G, Vernaci C, Franchi C, et al (2004) 5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy. Int J STD AIDS 15 (1): 17–20PubMedCrossRefGoogle Scholar
  61. Wieland U, Brockmeyer NH, Weissenborn SJ, Hochdorfer B, Stucker M, Swoboda J, et al (2006) Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol 142 (11): 1438–1444PubMedCrossRefGoogle Scholar
  62. Kaspari M, Gutzmer R, Kaspari T, Kapp A, Brodersen JP (2002) Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. Br J Dermatol 147 (4): 757–759PubMedCrossRefGoogle Scholar
  63. Ulrich C, Busch JO, Meyer T, Nindl I, Schmook T, Sterry W, et al (2006) Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 155 (2): 451–454PubMedCrossRefGoogle Scholar
  64. Hughes LL, Rich TA, Delclos L, Ajani JA, Martin RG (1989) Radiotherapy for anal cancer: experience from 1979–1987. Int J Radiat Oncol Biol Phys 17 (6): 1153–1160PubMedCrossRefGoogle Scholar
  65. Joon DL, Chao MW, Ngan SY, Joon ML, Guiney MJ (1999) Primary adenocarcinoma of the anus: a retrospective analysis. Int J Radiat Oncol Biol Phys 45 (5): 1199–1205PubMedCrossRefGoogle Scholar
  66. Nigro ND, Vaitkevicius VK, Considine B Jr (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17 (3): 354–356PubMedCrossRefGoogle Scholar
  67. Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ (1983) Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 51 (10): 1826–1829PubMedCrossRefGoogle Scholar
  68. Cummings BJ, Keane TJ, O'Sullivan B, Wong CS, Catton CN (1991) Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 21 (5): 1115–1125PubMedCrossRefGoogle Scholar
  69. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15 (5): 2040–2049PubMedGoogle Scholar
  70. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14 (9): 2527–2539PubMedGoogle Scholar
  71. John M, Pajak T, Flam M, Hoffman J, Markoe A, Wolkov H, et al (1996) Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92–08. Cancer J Sci Am 2 (4): 205–211PubMedGoogle Scholar
  72. ASCO Annual Meeting Proceedings Part I (2006) J Clin Oncol 24 (18) (June 20 Supplement): 4009Google Scholar
  73. Blazy A, Hennequin C, Gornet JM, Furco A, Gérard L, Lémann M, et al (2005) Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 48: 1176–1181PubMedCrossRefGoogle Scholar
  74. Stadler RF, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL (2004) Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum 47: 1305–1309PubMedCrossRefGoogle Scholar
  75. Rich TA, Ajani JA, Morrison WH, Ota D, Levin B (1993) Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol 27 (3): 209–215PubMedCrossRefGoogle Scholar
  76. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, et al (2007) Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 14 (2): 478–483PubMedCrossRefGoogle Scholar
  77. Ferenschild FT, Vermaas M, Hofer SO, Verhoef C, Eggermont AM, de Wilt JH (2005) Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg 29 (11): 1452–1457PubMedCrossRefGoogle Scholar
  78. Damin DC, Rosito MA, Schwartsmann G (2006) Sentinel lymph node in carcinoma of the anal canal: a review. Eur J Surg Oncol 32 (3): 247–252PubMedCrossRefGoogle Scholar
  79. Benson E (2004) Imiquimod: potential risk of an immunostimulant. Australas J Dermatol 45 (2): 123–124PubMedCrossRefGoogle Scholar
  80. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM (2005) Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 141 (8): 985–993PubMedCrossRefGoogle Scholar
  81. Aigner F, Boeckle E, Albright J, Kilo J, Boesmueller C, Conrad F, et al (2007) Malignancies of the colorectum and anus in solid organ recipients. Transpl Int 1: 497–504CrossRefGoogle Scholar
  82. Palefsky J (2006) CHAPTER 5 HPV infection and HPV-associated neoplasia in immunocompromised women. Int J Gynaecol Obstet 94 [Suppl 1]: 56–64CrossRefGoogle Scholar
  83. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid proteins self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89: 12180–12184PubMedPubMedCentralCrossRefGoogle Scholar
  84. Kirnbauer R, Taub J, Greenstone H, Roden R, Dürst M, Gissmann L, et al (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1 plus L2 into virus-like particles. J Virol 67 (12): 6929–6936PubMedPubMedCentralGoogle Scholar
  85. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (5): 271–278PubMedCrossRefGoogle Scholar
  86. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al (2006) HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (9518): 1247–1255PubMedCrossRefGoogle Scholar
  87. Editorial (2006) Should HPV vaccines be mandatory for all adolescents? The Lancet 368: 1212Google Scholar
  88. Birner P, Schindl M, Stani J, Oberhuber G, Czerwenka K, Vutuc C, et al (2000) Hybrid capture based human papillomavirus typing in cervical screening compared to cytology and histology. Wien Klin Wochenschr 112 (17): 761–766PubMedGoogle Scholar
  89. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al (2007) American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57 (1): 7–28PubMedCrossRefGoogle Scholar
  90. Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Boden E, et al (1995) Lifetime number of partners as the only independent risk factor for human papillomavirus-infection: a population based study. Sex Transm Dis 22: 119–127PubMedCrossRefGoogle Scholar
  91. Ferenczy A, Bergeron C, Richart RM (1989) Human papillomavirus DNA in Fomites on objects used for the management of patients with genital human papillomavirus infections. Obstet Gynecol 4: 950–954Google Scholar
  92. Manhart L, Koutsky L (2002) Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29: 725–735PubMedCrossRefGoogle Scholar
  93. Bleeker MC, Berkhof J, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Starink TM, et al (2005) HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer 92: 1388–1392PubMedPubMedCentralCrossRefGoogle Scholar
  94. Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, et al (2003) Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 107 (5): 811–816PubMedCrossRefGoogle Scholar
  95. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al (2006) Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354 (25): 2645–2654PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Felix Aigner
    • 1
  • Friedrich Conrad
    • 1
  • Andreas Widschwendter
    • 2
  • Robert Zangerle
    • 3
  • Bettina Zelger
    • 4
  • Alfred Haidenberger
    • 5
  • Sebastian Roka
    • 6
  • Kurt Heim
    • 2
  • Reinhard Höpfl
    • 3
  • Martin Klimpfinger
    • 7
  • Yves Marcus Rigler
    • 8
  • Hugo Bonatti
    • 9
  • Johann Pfeifer
    • 8
  • Andrea Maier
    • 10
  • Reinhard Kirnbauer
    • 11
  • Andreas Salat
    • 6
  1. 1.Universitätsklinik für Visceral-, Transplantations- und ThoraxchirurgieMedizinische Universität InnsbruckInnsbruckAustria
  2. 2.Universitätsklinik für Frauenheilkunde, Klinische Abteilung für Gynäkologie und GeburtshilfeMedizinische Universität InnsbruckInnsbruckAustria
  3. 3.Universitätsklinik für Dermatologie und VenerologieMedizinische Universität InnsbruckInnsbruckAustria
  4. 4.Institut für PathologieMedizinische Universität InnsbruckInnsbruckAustria
  5. 5.Universitätsklinik für Strahlentherapie-RadioonkolgieMedizinische Universität InnsbruckInnsbruckAustria
  6. 6.Universitätsklinik für Chirurgie, Klinische Abteilung für AllgemeinchirurgieMedizinische Universität WienWienAustria
  7. 7.Pathologisch-bakteriologisches InstitutSozialmedizinisches Zentrum Süd – Kaiser-Franz-Josef-SpitalWienAustria
  8. 8.Universitätsklinik für Chirurgie, Klinische Abteilung für AllgemeinchirurgieMedizinische Universität GrazGrazAustria
  9. 9.Department of SurgeryUniversity of Virginia HealthsystemCharlottesvilleUSA
  10. 10.Universitätsklinik für RadiodiagnostikMedizinische Universität WienWienAustria
  11. 11.Universitätsklinik für Dermatologie, Abteilung für Immundermatologie und infektiöse HautkrankheitenMedizinische Universität WienWienAustria

Personalised recommendations